I took time to explain and answer , unfortunately can be misconceived .
Hope this part helps
Really - This study for ARDS involving DXB200 as well as many other drug treatments existing :
***Has truly - nothing to do with Mesoblast. ****
There is not a quick outcome likely for determining optimal drug combination treatments for ARDS , in Covid -19 —but they must work out what is best , out of all drug treatments that are available. ( or in studies and ‘available.” )
Anti- inflammatory activity is a key need- to reduce lung fibrosis post- recovery .
( as well as for prevention of heart ! damage . Notably - Mesoblast longterm phase 3 trial CHF readout is imminent . And above in here another poster has highlighted today the efficacy that is indicated for Mesoblast MSCs in chronic heart failure trial patients )
***Drug anti inflammatory treatments- are chalk and cheese compared to stem cells ***
Mesoblast represents - a paradigm medical treatment shift , and far preferred moving into the future , imo .
Anti -coagulation prescription early is likely most important , with perhaps the lowering of blood pressure and inflammation management .
Covid - 19 is a vascular disease with systemic effects , everywhere , in the worst cases - including in the kidneys , and heart and liver , with blood clotting , as well as inflammation in the blood vessels with associated terrible outcomes .
All interfacing with the acute respiratory condition - the acute pneumonia with the lungs overwhelmed due to the viral respiratory disease. Even if the lungs are not completely overwhelmed and /or if the patient is ventilated to try to maximise oxygen flow to the base of the lungs as much as possible— the blood vessels can be so compromised and unable to collect the oxygen from the lungs even when patient is fully ventilated .
Systemic emergency treatment is also rapidly needed to prevent deterioration when all else has failed in Covid -19 ARDS patients . DX200 , or any drug combination to me , is for trying to get the adjunct effects - earlier really .
To explain the differences & how is no effect at all on mesoblast in Covid - 19 ARDS .
** Of course I think that stem cells will be far superior also in deteriorating chronic kidney disease as well .
**Stem cell treatment is a paradigm shift in medical management.
A great post by vinn and others above . Thankyou.
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-3225
-
- There are more pages in this discussion • 14,600 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.20 |
Change
-0.105(8.05%) |
Mkt cap ! $1.364B |
Open | High | Low | Value | Volume |
$1.27 | $1.30 | $1.17 | $12.26M | 9.967M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 38602 | $1.20 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.20 | 31698 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 9584 | 1.190 |
17 | 68131 | 1.185 |
17 | 166852 | 1.180 |
11 | 79698 | 1.175 |
12 | 97362 | 1.170 |
Price($) | Vol. | No. |
---|---|---|
1.195 | 55236 | 14 |
1.200 | 50287 | 18 |
1.205 | 119045 | 14 |
1.210 | 57297 | 9 |
1.215 | 38425 | 4 |
Last trade - 12.11pm 24/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online